Ampicillin

證據等級: L5

預測適應症: 10 個

Ampicillin: From Bacterial Infections to Laryngitis

One-Sentence Summary

Ampicillin is a broad-spectrum beta-lactam antibiotic historically used to treat a wide range of bacterial infections, including respiratory tract, urinary tract, and soft tissue infections. The TxGNN model predicts it may be effective for Laryngitis, with 1 clinical trial and 20 publications currently identified in support of this direction. However, the available evidence is indirect — the single trial involved a related combination antibiotic, and the literature largely reflects case reports and observational studies rather than direct ampicillin-in-laryngitis trials.

Quick Overview

Item	Content
Original Indication	Broad-spectrum bacterial infections (no Saudi Arabia regulatory registration on record)
Predicted New Indication	Laryngitis
TxGNN Prediction Score	99.97%
Evidence Level	L3 (observational studies and guideline review)
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacology, ampicillin is an aminopenicillin beta-lactam antibiotic that acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), ultimately causing bacteriolysis. Its spectrum includes streptococci, enterococci, Listeria, and — in the pre-resistance era — Haemophilus influenzae type b and Neisseria gonorrhoeae.

The mechanistic rationale for laryngitis is plausible but context-dependent. Bacterial laryngitis is most commonly caused by H. influenzae type b (classically associated with acute epiglottitis), Streptococcus pyogenes, and Streptococcus pneumoniae — all organisms historically within ampicillin's coverage. Prior to widespread Hib vaccination and the emergence of beta-lactamase-producing strains, ampicillin was a first-line agent for H. influenzae epiglottitis. Multiple cohort studies from the 1970s–1990s describe its clinical use in this context.

However, two key limitations constrain this prediction. First, the majority of laryngitis cases are viral in origin, and antibiotics offer no benefit for viral laryngitis. Second, the prevalence of beta-lactamase-producing H. influenzae has risen substantially since the 1980s, eroding ampicillin monotherapy effectiveness for bacterial upper airway infections. Current guidelines recommend ampicillin-sulbactam or third-generation cephalosporins rather than ampicillin alone for confirmed bacterial laryngitis. The TxGNN high-score prediction likely reflects the strong graph-network co-occurrence between ampicillin and upper respiratory tract infection nodes, rather than a direct, validated treatment relationship.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01406275	N/A (Post-marketing surveillance)	Completed	363	Post-marketing safety/efficacy study of amoxicillin/clavulanate (CLAVAMOX®) in Japanese paediatric patients with multiple indications including laryngitis; direct ampicillin evidence is not provided

Note: No registered clinical trials directly evaluating ampicillin monotherapy for laryngitis were identified.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39879424	2025	Guideline Review	CoDAS	Quality assessment (AGREE II) of clinical guidelines for laryngitis and pharyngitis management; provides methodological framework for evidence-based antibiotic decision-making
5314768	1971	Cohort	British Medical Journal	Early cohort describing epiglottitis in adults with antibiotic management context
3977063	1985	Cohort	Anaesthesia and Intensive Care	Review of 161 paediatric acute epiglottitis cases (1975–1984); describes airway management and antibiotic use, with five deaths; contextualises severity of bacterial laryngeal disease
25944348	2015	Cohort	Otolaryngology–Head and Neck Surgery	Hospital-level variation in perioperative antibiotic choice for laryngectomy and its association with surgical site infection rates; highlights importance of antibiotic selection in laryngeal surgery
6465636	1984	Case Series	Annals of Emergency Medicine	Three adult epiglottitis cases; emphasises diagnostic difficulty and antibiotic treatment in acute upper airway obstruction
2603419	1989	Cohort	Western Journal of Medicine	Nine adult acute epiglottitis cases over 2 years; intubation required in 44%; describes antibiotic treatment and outcomes
35923122	2023	Case Report	Annals of Otology, Rhinology, and Laryngology	Novel case of spontaneous laryngeal abscess in uncontrolled diabetes; historical review of modern cases in the antibiotic era; notes rarity since introduction of broad-spectrum antibiotics
30579693	2019	Case Report	Auris Nasus Larynx	Laryngeal actinomycosis post-bone marrow transplantation; treated with high-dose penicillin (ampicillin-class); supports beta-lactam use in specific bacterial laryngeal infections
34986973	2023	Case Report	Auris Nasus Larynx	COVID-19-associated acute epiglottitis requiring emergency airway management; underscores need for broad-spectrum antibiotic cover in severe laryngeal presentations
1712371	1991	Case Series	Journal of Clinical Gastroenterology	Short-term antibiotic treatment of Whipple's disease in 19 patients; one patient specifically treated with ampicillin 2 g/day with clinical response — indirect evidence of ampicillin activity in systemic infectious disease context

Saudi Arabia Market Information

Ampicillin has no registered pharmaceutical licenses in Saudi Arabia (SFDA/NCBE database). The drug is not currently marketed in the Saudi market.

Safety Considerations

Please refer to the package insert for safety information.

Note: Safety data including key warnings, contraindications, and drug interactions were not retrievable in this Evidence Pack (classified as data gaps DG001 and DG002). Clinicians should consult the current SmPC or product labelling before any clinical application. Known class-level concerns for beta-lactam penicillins include hypersensitivity reactions (including anaphylaxis), ampicillin-associated maculopapular rash (particularly in patients with Epstein-Barr virus infection or CLL), and Clostridioides difficile-associated diarrhoea.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model's high prediction score (99.97%) for ampicillin in laryngitis is mechanistically plausible for bacterial laryngitis caused by H. influenzae or streptococcal species, but current evidence is limited to indirect observational data and case reports (L3). No clinical trial directly evaluates ampicillin monotherapy in laryngitis, and increasing beta-lactamase resistance among key pathogens substantially limits real-world clinical utility compared to newer agents or combination regimens.

To proceed, the following is needed:

Clarification of MOA data (DrugBank API query — flagged as DG002 High severity)
Retrieval of current Saudi Arabia SmPC/warnings and contraindications (DG001 Blocking)
Drug-drug interaction data (DDI query returned not_found; re-query recommended)
A targeted literature review distinguishing viral vs. bacterial laryngitis populations and identifying any head-to-head comparison of ampicillin against current standard-of-care (ampicillin-sulbactam or cephalosporins) in bacterial upper airway infections
Epidemiological data on local H. influenzae beta-lactamase prevalence in the target market to assess whether ampicillin monotherapy retains residual clinical viability
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.